Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T20:31:27.947Z.
Calculation as of: 2026-10-06T20:31:27.947Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5aadd97284981d173c87413c67de95801d58f7ce8cc73935cbfc70b12a62615a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.75B
EV/Sales Ratio
1.65x
TTM Avg
1.73x
3Y Avg
2.06x
5Y Avg
2.34x
Market Cap
$1.74B
EV/Sales Ratio
1047.76x
TTM Avg
394.01x
3Y Avg
178.14x
5Y Avg
125.14x
Market Cap
$1.74B
EV/Sales Ratio
5.68x
TTM Avg
4.42x
3Y Avg
3.97x
5Y Avg
3.99x
Market Cap
$1.74B
EV/Sales Ratio
0.30x
TTM Avg
0.88x
3Y Avg
0.84x
5Y Avg
1.02x
Market Cap
$1.81B
EV/Sales Ratio
7.51x
TTM Avg
9.45x
3Y Avg
9.08x
5Y Avg
8.22x
Market Cap
$1.73B
EV/Sales Ratio
28.50x
TTM Avg
23.63x
3Y Avg
32.34x
5Y Avg
67.27x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Generate Biomedicines, Inc. (GENB) | $1.77B | N/A | N/A | N/A | N/A |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 1.65x | 1.73x | 2.06x | 2.34x |
| Novocure Ltd (NVCR)vs › | $1.74B | 2.69x | 2.87x | 3.71x | 7.97x |
| Absci Corporation (ABSI)vs › | $1.74B | 1047.76x | 394.01x | 178.14x | 125.14x |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | 5.68x | 4.42x | 3.97x | 3.99x |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 0.30x | 0.88x | 0.84x | 1.02x |
| Xencor, Inc. (XNCR)vs › | $1.81B | 17.40x | 10.69x | 9.34x | 9.27x |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 7.51x | 9.45x | 9.08x | 8.22x |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | 28.50x | 23.63x | 32.34x | 67.27x |
| Azenta, Inc. (AZTA)vs › | $1.81B | 2.73x | 1.90x | 2.97x | 4.80x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
